Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지

Frequency of K-RAS and N-RAS Gene Mutations in Colorectal Cancers in Southeastern Iran

  • Naseri, Mohsen (Genomics Research Center, Paramedical Faculty, University of Medical Sciences) ;
  • Sebzari, Ahmadreza (Oncology, Medical Faculty, University of Medical Sciences) ;
  • Haghighi, Fatemeh (Pathology, Faculty of Medicine, University of Medical Sciences) ;
  • Hajipoor, Fatemeh (Animal Physiology, Research Center of Genomics, University of Medical Sciences) ;
  • Razavi, Fariba Emadian (Department of Prosthodontics, Faculty of Dentistry, Genomics Research Center, University of Medical Sciences)
  • Published : 2016.09.01
⟨ Previous Next ⟩

Abstract

Background: K-RAS and N-RAS gene mutations cause resistance to treatment in patients with colorectal cancer. Based on this, awareness of mutation of these genes is considered a clinically important step towards better diagnosis and appropriate treatment. Materials and Methods: Fifty paraffin-embedded blocks of colorectal cancer were obtained from Imam Reza Hospital of Birjand, Iran. Following DNA extraction, the samples were analyzed for common mutations of exons 2, 3 and 4 of KRAS and NRAS genes using real time PCR and pyrosequencing. Results: According to this study, the prevalence of mutations was respectively 28% (14 out of 50) and 2% (1 out of 50) in KRAS and NRAS genes. All the mutations were observed in patients >50 years old. Conclusions: Mutations were found in both KRAS and NRAS genes in colorectal cancers in Iranian patients. Determining the frequency of these mutations in each geographical region may be necessary to benefit from targeted cancer therapy.

Keywords

References

  1. Abuli A, Fernandez-Rozadilla C, Giraldez MD, et al (2011). A two-phase case-control study for colorectal cancer genetic susceptibility: candidate genes from chromosomal regions 9q22 and 3q22. Br J Cancer, 105, 870-5. https://doi.org/10.1038/bjc.2011.296
  2. Alshahid M, Wakil SM, Al-Najai M, et al (2013). New susceptibility locus for obesity and dyslipidaemia on chromosome 3q22.3. Hum Genomics, 7, 15. https://doi.org/10.1186/1479-7364-7-15
  3. Amado RG, Wolf M, Peeters M, et al (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol, 26, 1626-34. https://doi.org/10.1200/JCO.2007.14.7116
  4. Arrington AK, Heinrich EL, Lee W, et al (2012). Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci, 13, 12153-68. https://doi.org/10.3390/ijms131012153
  5. Bagadi SB, Sanghvi M, Nair SB, et al (2012). Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma. Int J Biol Markers, 27, 27-33. https://doi.org/10.5301/JBM.2012.9108
  6. Chen J, Guo F, Shi X, et al (2014). BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients. BMC Cancer, 14, 802. https://doi.org/10.1186/1471-2407-14-802
  7. Chretien AS, Harle A, Meyer-Lefebvre M, et al (2013). Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancer. Cancer Med, 2, 11-20. https://doi.org/10.1002/cam4.47
  8. De Stefano A, Carlomagno C (2014). Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. World J Gastroenterol, 20, 9732-43. https://doi.org/10.3748/wjg.v20.i29.9732
  9. Douillard JY, Oliner KS, Siena S, et al (2013). Panitumumab- FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med, 369, 1023-34. https://doi.org/10.1056/NEJMoa1305275
  10. Edalat H, Sadeghizadeh M, Jamali M (1385). Mutation detection in codon 12 K-ras gene in patients with colorectal cancer using PCR-RFLP method. J Med Sci Modares, 9, 33-8.
  11. Er TK, Chen CC, Bujanda L, et al (2014). Current approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patients. Biomed Res Int, 2014, 591867.
  12. Golfam F, Golfam P, Neghabi Z (2013). Frequency of all types of colorectal tumors in the patients referred to selected hospitals in Tehran. Iranian Red Crescent Med J, 15, 473-6. https://doi.org/10.5812/ircmj.4026
  13. Herreros-Villanueva M, Rodrigo M, Claver M, et al (2011). KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. Mol Biol Rep, 38, 1315-20. https://doi.org/10.1007/s11033-010-0232-x
  14. Lari S, Ghafarzadegan K, Afsharnegad S, et al (1390). Mutation detection in codon 13 K-ras gene in patients with colorectal cancer in North East Iran. New genetics, 6, 43-7.
  15. Lievre A, Bachet JB, Le Corre D, et al (2006). KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res, 66, 3992-5. https://doi.org/10.1158/0008-5472.CAN-06-0191
  16. Neumann J, Zeindl-Eberhart E, Kirchner T, et al (2009). Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract, 205, 858-62. https://doi.org/10.1016/j.prp.2009.07.010
  17. Pietrantonio F, Petrelli F, Coinu A, et al (2015). Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer, 51, 587-94. https://doi.org/10.1016/j.ejca.2015.01.054
  18. Roya Dolatkhah SD, Mohammad Hossein Somi, Morteza Jabbarpour, et al (2015). Common KRAS and BRAF Mutations in Colorectal Cancer Patients. Digest, 20, 27-33.
  19. Senguven B, Baris E, Oygur T, et al (2014). Comparison of Methods for the Extraction of DNA from Formalin-Fixed, Paraffin-Embedded Archival Tissues. Int J Med Sci, 11, 494-9. https://doi.org/10.7150/ijms.8842
  20. Shemirani AI, Haghighi MM, Milanizadeh S, et al (2011). The role of kras mutations and MSI status in diagnosis of colorectal cancer. Gastroenterol Hepatol Bed Bench, 4, 70-5.
  21. Shen Y, Wang J, Han X, et al (2013). Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PLoS One, 8, 81628. https://doi.org/10.1371/journal.pone.0081628
  22. Sobhani S, Ggafarpour M, Mostakhdemin Hossaini Z, et al (2009). Prevalence of common mutations in codons 12 and 13 kras gene in patients with colorectal cancer in Iranian population. Genetics Third Millennium, 8, 2011-8.
  23. Symvoulakis EK, Zaravinos A, Panutsopulos D, et al (2007). Highly conserved sequence of exon 15 BRAF gene and KRAS codon 12 mutation among Greek patients with colorectal cancer. Int J Biol Markers, 22, 12-8. https://doi.org/10.5301/JBM.2008.1785
  24. Tan C, Du X (2012). KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol, 18, 5171-80.
  25. Trevisiol C, Di Fabio F, Nascimbeni R, et al (2006). Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases. Int J Biol Markers, 21, 223-8. https://doi.org/10.5301/JBM.2008.3336
  26. Wang Y, Velho S, Vakiani E, et al (2013). Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression. Cancer Discov, 3, 294-307. https://doi.org/10.1158/2159-8290.CD-12-0198
  27. Wolpin BM, Bass AJ (2014). Managing advanced colorectal cancer: have we reached the PEAK with current therapies? J Clin Oncol, 32, 2200-2. https://doi.org/10.1200/JCO.2014.55.6316